# Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

> **NCT02593773** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 86 (actual)

## Conditions studied

- Friedreich's Ataxia

## Interventions

- **DRUG:** Interferon γ-1b

## Key facts

- **NCT ID:** NCT02593773
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-25
- **Primary completion:** 2017-03-21
- **Final completion:** 2017-03-21
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593773, "Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT02593773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*